Skip to content
Company Analysis

LUCYW

A comprehensive view of key metrics, scores, and financial health for

Overview of LUCYW

LUCYW NCM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics
LUCYW (LUCYW), in the Medical Instruments & Supplies industry, last closed at $0.04, about 0.0% overvalued vs fair value, -61.7% 1Y return, ranked 1026/1122 in sector.
$ 0.04
-1.79%
(Delayed)
• Vol 90d: 160.1%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Weak
Health
Weak
Efficiency
Weak
Growth
Good
Profitability
Weak
Health
Weak
Efficiency
Weak
Completeness: 56%
Confidence: 38%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.lucyd.co
HQ North Miami, FL
Employees 11
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.6M
42%%
Gross Profit
$215.2K
280.3%%
Operating Income (GAAP)
$-7.9M
-15.6%%
EBITDA
$-7.6M
-15.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
13.1%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating 's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
27
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
12
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing LUCYW's balance between Growth (66.0%), Profitability (11.5%), and Safety (22.6%). Growth 66% Safety 23% Profitability 11%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

87th percentile vs peers
88
Key Signals
Rev Growth YoY 42.0% 88p Revenue CAGR 3Y 33.3% 85p Asset Growth YoY 58.2% 95p
Strengths
  • Growth performance in top 20% of peers (percentile: 87)
  • Rev Growth YoY in top 20% of peers (42.0%, 88th percentile)
  • Revenue CAGR 3Y in top 20% of peers (33.3%, 85th percentile)
  • Equity/Assets in top 20% of peers (92.5%, 97th percentile)
Risks

No significant risks identified for this axis.

Profitability

15th percentile vs peers
15
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

30th percentile vs peers
30
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for .

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000